AINDEX
Markets

IRulya Therapeutics Inc. (IRLA)

IRLANASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)

$41.12

+2.67 (+6.94%) today

Regular session, Nov 18, 3:01 PM ET

+6.94% 1D
Market cap
$445.80m
P/E
–
EPS, last 4 quarters
$-111.23
Dividend yield
–
Day range
$37.94 to $42.73
52-week range
$15.10 to $909.98
Average volume
–
Previous close
$38.45

Analysts

8 covering

Buy8 buy, 0 hold, 0 sell

Targets a year out average $77.00, +87.3% from here

$68.00now $41.12$98.00

Earnings

next estimate $-0.9700

Next report

Dec 2025

–

Mar 2026

–

Jun 2026

+63.0%

Sep 2026

-33.3%

estimate reported, and the surprise

Financials

No quarterly figures from the source.

News

8 latest

The company

IRulya Therapeutics Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a clinical study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b clinical study in PH-ILD is ongoing, and a Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.